» Articles » PMID: 32932943

Metabolic Constrains Rule Metastasis Progression

Overview
Journal Cells
Publisher MDPI
Date 2020 Sep 16
PMID 32932943
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis formation accounts for the majority of tumor-associated deaths and consists of different steps, each of them being characterized by a distinctive adaptive phenotype of the cancer cells. Metabolic reprogramming represents one of the main adaptive phenotypes exploited by cancer cells during all the main steps of tumor and metastatic progression. In particular, the metabolism of cancer cells evolves profoundly through all the main phases of metastasis formation, namely the metastatic dissemination, the metastatic colonization of distant organs, the metastatic dormancy, and ultimately the outgrowth into macroscopic lesions. However, the metabolic reprogramming of metastasizing cancer cells has only recently become the subject of intense study. From a clinical point of view, the latter steps of the metastatic process are very important, because patients often undergo surgical removal of the primary tumor when cancer cells have already left the primary tumor site, even though distant metastases are not clinically detectable yet. In this scenario, to precisely elucidate if and how metabolic reprogramming drives acquisition of cancer-specific adaptive phenotypes might pave the way to new therapeutic strategies by combining chemotherapy with metabolic drugs for better cancer eradication. In this review we discuss the latest evidence that claim the importance of metabolic adaptation for cancer progression.

Citing Articles

Genetic Contribution of the Adrenergic, Cholinergic, and Serotonergic Systems to Leiomyoma Development and Treatment.

Inacio A, Aguiar L, Carrilho R, Pires P, Ferreira J, Coelho L Int J Mol Cell Med. 2024; 12(4):320-334.

PMID: 39006196 PMC: 11240054. DOI: 10.22088/IJMCM.BUMS.12.4.320.


Deep neural network for discovering metabolism-related biomarkers for lung adenocarcinoma.

Fu L, Li M, Lv J, Yang C, Zhang Z, Qin S Front Endocrinol (Lausanne). 2023; 14:1270772.

PMID: 37955007 PMC: 10634586. DOI: 10.3389/fendo.2023.1270772.


Breast cancers as ecosystems: a metabolic perspective.

Martino F, Lupi M, Giraudo E, Lanzetti L Cell Mol Life Sci. 2023; 80(9):244.

PMID: 37561190 PMC: 10415483. DOI: 10.1007/s00018-023-04902-9.


Metabolomics-Guided Identification of a Distinctive Hepatocellular Carcinoma Signature.

Tambay V, Raymond V, Goossens C, Rousseau L, Turcotte S, Bilodeau M Cancers (Basel). 2023; 15(12).

PMID: 37370840 PMC: 10296227. DOI: 10.3390/cancers15123232.


Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance.

Azam A, Sounni N Cancers (Basel). 2022; 14(24).

PMID: 36551752 PMC: 9776509. DOI: 10.3390/cancers14246267.


References
1.
Chen F, Zhou J, Li Y, Zhao Y, Yuan J, Cao Y . YY1 regulates skeletal muscle regeneration through controlling metabolic reprogramming of satellite cells. EMBO J. 2019; 38(10). PMC: 6518041. DOI: 10.15252/embj.201899727. View

2.
Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

3.
Libiad M, Vitvitsky V, Bostelaar T, Bak D, Lee H, Sakamoto N . Hydrogen sulfide perturbs mitochondrial bioenergetics and triggers metabolic reprogramming in colon cells. J Biol Chem. 2019; 294(32):12077-12090. PMC: 6690701. DOI: 10.1074/jbc.RA119.009442. View

4.
Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

5.
Camarda R, Zhou A, Kohnz R, Balakrishnan S, Mahieu C, Anderton B . Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016; 22(4):427-32. PMC: 4892846. DOI: 10.1038/nm.4055. View